Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue ACS Central Science Année : 2021

Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines

Résumé

The development of recombinant COVID-19 vaccines has resulted from scientific progress made at an unprecedented speed during 2020. The recombinant spike glycoprotein monomer, its trimer, and its recombinant receptorbinding domain (RBD) induce a potent anti-RBD neutralizing antibody response in animals. In COVID-19 convalescent sera, there is a good correlation between the antibody response and potent neutralization. In this review, we summarize with a critical view the molecular aspects associated with the interaction of SARS-CoV-2 RBD with its receptor in human cells, the angiotensin-converting enzyme 2 (ACE2), the epitopes involved in the neutralizing activity, and the impact of virus mutations thereof. Recent trends in RBD-based vaccines are analyzed, providing detailed insights into the role of antigen display and multivalence in the immune response of vaccines under development.
Fichier principal
Vignette du fichier
Valdes,ACS CentralSci 2021.pdf (4.86 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04446345 , version 1 (08-02-2024)

Identifiants

Citer

Yury Valdes-Balbin, Darielys Santana-Mederos, Françoise Paquet, Sonsire Fernandez, Yanet Climent, et al.. Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines. ACS Central Science, 2021, 7, pp.757 - 767. ⟨10.1021/acscentsci.1c00216⟩. ⟨hal-04446345⟩
1 Consultations
4 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More